title: Notable deals in the pharmaceutical industry in the third quarter of 2016.
abstract: During the third quarter of 2016, Cortellis Competitive Intelligence had 865 new deals added as part of its ongoing coverage of pharmaceutical licensing activity. This figure shows similar deal activity compared with the same quarter of 2015 (934), and 21% less than the previous quarter, although they had similar disclosed financial sizes in comparison with the first half of 2016. This article will focus on a number of the most valuable and notable deals forged during the quarter, as well as a selection of deals from some of the most prolific deal makers. An update on milestones, options and terminated deals of significance will also be presented, along with an early outlook on the last quarter of 2016's pharmaceutical licensing activity.
authors.affiliation: Thomson Reuters, Barcelona, Spain. elisabet.cruces@tr.com.
authors.forename: E
authors.initials: E
authors.lastname: Cruces
mesh_terms: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D032982:Contracts; D004345:Drug Industry; D006801:Humans; D008004:Licensure
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents
keywords: Agreements; Deals; Milestones; Pharmaceutical industry